Interim report 1 January - 30 September 2008
Three months ended 30 September 2008
§ Local currency sales increased by 32% and Euro sales increased by
30% to ¤299.6m (¤229.6m).
§ Average size of the sales force increased by 22% to 2.62m
consultants and closing sales force was up by 27%.
§ EBITDA increased by 41% to ¤36.8m (¤26.1m).
§ Operating margin, was 9.7% (8.6%) and operating profit increased
by 48% to ¤29.2m (¤19.7m).
§ Net profit increased by 93% to ¤23.1m (¤11.9m).
§ EPS after dilution increased by 92% to ¤0.41 (¤0.21).
§ Oriflame issued a trading statement on 3 October with a revised
full year outlook: sales growth for 2008 expected to be above 20% in
local currency and the operating margin expected to improve compared
to 2007.
Nine months ended 30 September 2008
§ Local currency sales increased by 26% and Euro sales increased by
22% to ¤934.7m (¤767.8m).
§ Net profit before restructuring costs increased by 30% to ¤93.8m
(¤72.4m).
§ EPS after dilution and before restructuring costs increased by 30%
to ¤1.66 (¤1.28). Diluted EPS after restructuring costs amounted to
¤1.51 (¤1.07).
§ Cash flow from operating activities decreased to ¤5.1m (¤40.2),
mainly due to an inventory build up and the cash impact from the
restructuring programme.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.